B
BioInvent International AB
STO:BINV
BioInvent International AB
STO:BINV
Price:
26.5
SEK
-5.36%
Market Closed
Market Cap:
1.7B
SEK
BioInvent International AB
Cash Interest Paid
|
BioInvent International AB
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioInvent International AB
STO:BINV
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Cash Interest Paid
kr1.9m
|
CAGR 3-Years
17%
|
CAGR 5-Years
121%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Cash Interest Paid
kr1.1B
|
CAGR 3-Years
50%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BioInvent International AB
Glance View
BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
BINV
Intrinsic Value
84.78
SEK
Undervaluation 69%
B
You don't have any saved screeners yet